Overview Dividends

(AMRN) Amarin - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: US0231114044

Omega-3, Cardiovascular, Triglyceride, Capsule

AMRN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -1.88%
EPS Trend (3Y Correlation): -42.7%

AMRN Revenue

Revenue Growth (3Y CAGR): -21.24%
Revenue Trend (3Y Correlation): -88.9%

Description: AMRN Amarin October 26, 2025

Amarin Corporation plc is a Dublin-based biopharma focused on developing and commercializing cardiovascular therapeutics, most notably VASCEPA - a prescription omega-3 fatty acid (EPA) indicated to lower triglycerides in adults with severe hypertriglyceridemia. The company distributes VASCEPA primarily through U.S. wholesalers, regional partners, and specialty pharmacies, and it maintains a development partnership with Japan’s Mochida Pharmaceutical to explore additional EPA-based indications.

From a quantitative perspective, VASCEPA generated roughly $1.0 billion in net sales in 2023, driven by the 2022 FDA approval for a secondary indication of reducing major adverse cardiovascular events (the REDUCE-IT trial). The product’s patent protection runs through 2027 in the United States, after which generic competition could compress margins; meanwhile, the global market for triglyceride-lowering therapies is projected to grow at a 5-6% CAGR, supported by an aging population and rising prevalence of metabolic syndrome. Amarin’s FY2024 guidance reflects a modest sales growth assumption of 3-4% year-over-year, implicitly betting on continued uptake of the cardiovascular risk-reduction label and limited price erosion.

If you’re interested in a deeper, data-driven assessment of Amarin’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can help you surface the most relevant metrics and scenario analyses.

AMRN Stock Overview

Market Cap in USD	408m
Sub-Industry	Biotechnology
IPO / Inception	1993-04-01

AMRN Stock Ratings

Growth Rating	-9.40%
Fundamental	18.1%
Dividend Rating	-
Return 12m vs S&P 500	18.8%
Analyst Rating	2.33 of 5

AMRN Dividends

Currently no dividends paid

AMRN Growth Ratios

Growth Correlation 3m	57.1%
Growth Correlation 12m	77.6%
Growth Correlation 5y	-92.8%
CAGR 5y	-16.45%
CAGR/Max DD 3y (Calmar Ratio)	-0.20
CAGR/Mean DD 3y (Pain Ratio)	-0.29
Sharpe Ratio 12m	-0.07
Alpha	14.02
Beta	0.625
Volatility	60.93%
Current Volume	75.3k
Average Volume 20d	99.9k
Stop Loss	14.6 (-7.1%)
Signal	-0.27

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-103.6m TTM) > 0 and > 6% of Revenue (6% = 11.6m TTM)

FCFTA -0.02 (>2.0%) and ΔFCFTA -0.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 217.8% (prev 177.5%; Δ 40.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -11.5m > Net Income -103.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (414.5m) change vs 12m ago 0.75% (target <= -2.0% for YES)

Gross Margin 42.54% (prev 55.95%; Δ -13.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 26.29% (prev 33.19%; Δ -6.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -11.4k (EBITDA TTM -97.4m / Interest Expense TTM 7000 ) >= 6 (WARN >= 3)

Altman Z'' -11.98

(A) 0.63 = (Total Current Assets 606.8m - Total Current Liabilities 185.9m) / Total Assets 670.1m

(B) -2.53 = Retained Earnings (Balance) -1.70b / Total Assets 670.1m

warn (B) unusual magnitude: -2.53 — check mapping/units

(D) -6.77 = Book Value of Equity -1.39b / Total Liabilities 205.2m

Total Rating: -11.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 18.07

1. Piotroski 0.50pt = -4.50

2. FCF Yield -9.89% = -4.95

3. FCF Margin -5.96% = -2.24

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda 1.44 = 1.06

6. ROIC - WACC (= -23.66)% = -12.50

7. RoE -21.18% = -2.50

8. Rev. Trend -88.87% = -6.67

9. EPS Trend -42.73% = -2.14

What is the price of AMRN shares?

As of November 09, 2025, the stock is trading at USD 15.71 with a total of 75,332 shares traded.
Over the past week, the price has changed by -3.56%, over one month by -18.47%, over three months by +4.04% and over the past year by +35.43%.

Is Amarin a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Amarin (NASDAQ:AMRN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 18.07 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMRN is around 13.76 USD . This means that AMRN is currently overvalued and has a potential downside of -12.41%.

Is AMRN a buy, sell or hold?

Amarin has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell AMRN.

Strong Buy: 0
Buy: 0
Hold: 1
Sell: 2
Strong Sell: 0

What are the forecasts/targets for the AMRN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	10.7	-32.1%
Analysts Target Price	10.7	-32.1%
ValueRay Target Price	15.3	-2.7%

AMRN Fundamental Data Overview October 27, 2025

Market Cap USD = 407.9m (407.9m USD * 1.0 USD.USD)
P/E Forward = 500.0
P/S = 1.8593
P/B = 0.7447
P/EG = -1.74
Beta = 0.625
Revenue TTM = 193.2m USD
EBIT TTM = -79.8m USD
EBITDA TTM = -97.4m USD
Long Term Debt = 7.34m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 7.34m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -140.5m USD (from netDebt column, last quarter)
Enterprise Value = 116.5m USD (407.9m + Debt 7.34m - CCE 298.7m)
Interest Coverage Ratio = -11.4k (Ebit TTM -79.8m / Interest Expense TTM 7000 )
FCF Yield = -9.89% (FCF TTM -11.5m / Enterprise Value 116.5m)
FCF Margin = -5.96% (FCF TTM -11.5m / Revenue TTM 193.2m)
Net Margin = -53.61% (Net Income TTM -103.6m / Revenue TTM 193.2m)
Gross Margin = 42.54% ((Revenue TTM 193.2m - Cost of Revenue TTM 111.0m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 59.81%)
Tobins Q-Ratio = 0.17 (Enterprise Value 116.5m / Total Assets 670.1m)
Interest Expense / Debt = 0.10% (Interest Expense 7000 / Debt 7.34m)
Taxrate = 5.12% (-689.0k / -13.4m)
NOPAT = -75.8m (EBIT -79.8m * (1 - 5.12%)) [loss with tax shield]
Current Ratio = 3.26 (Total Current Assets 606.8m / Total Current Liabilities 185.9m)
Debt / Equity = 0.02 (Debt 7.34m / totalStockholderEquity, last quarter 464.9m)
Debt / EBITDA = 1.44 (negative EBITDA) (Net Debt -140.5m / EBITDA -97.4m)
Debt / FCF = 12.20 (negative FCF - burning cash) (Net Debt -140.5m / FCF TTM -11.5m)
Total Stockholder Equity = 489.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.46% (Net Income -103.6m / Total Assets 670.1m)
RoE = -21.18% (Net Income TTM -103.6m / Total Stockholder Equity 489.0m)
RoCE = -16.08% (EBIT -79.8m / Capital Employed (Equity 489.0m + L.T.Debt 7.34m))
RoIC = -15.49% (negative operating profit) (NOPAT -75.8m / Invested Capital 489.0m)
WACC = 8.17% (E(407.9m)/V(415.2m) * Re(8.32%) + D(7.34m)/V(415.2m) * Rd(0.10%) * (1-Tc(0.05)))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.73%
Fair Price DCF = unknown (Cash Flow -11.5m)
EPS Correlation: -42.73 | EPS CAGR: -1.88% | SUE: 4.0 | # QB: 1
Revenue Correlation: -88.87 | Revenue CAGR: -21.24% | SUE: -0.64 | # QB: 0

Additional Sources for AMRN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle